ImmPACT Bio awarded $8 million CIRM grant for continued development of CAR T-Cell therapy for lupus 

Los Angeles-based ImmPACT Bio has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for its ongoing Phase 1b/2 study evaluating IMPT-514, a potentially first-in-class CD19/CD20 bispecific CAR T-cell therapy for the treatment of refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE).

SLE is a chronic, often severe, systemic autoimmune disease. It’s caused by an immune attack on healthy tissues and the development of widespread inflammation that results in tissue damage throughout the body. B cells – a type of white blood cell- are known to play an early and central role in disease pathogenesis.